Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

被引:18
作者
Huang, Jing Li [1 ]
Kizy, Scott [1 ]
Marmor, Schelomo [1 ]
Altman, Ariella [1 ]
Blaes, Anne [2 ]
Beckwith, Heather [2 ]
Tuttle, Todd M. [1 ]
Hui, Jane Yuet Ching [1 ]
机构
[1] Univ Minnesota, Dept Surg, Mayo Mail Code 195,420 Delaware St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA
关键词
Breast cancer; 21-Gene recurrence score; Oncotype DX; Grade; Progesterone receptor; ENDOCRINE THERAPY; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; ASSAY; ESTROGEN; IMPACT; CHEMOTHERAPY; VALIDATION; EQUATIONS;
D O I
10.1007/s10549-018-4955-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization.MethodsWe identified women between the ages of 18 and 74years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS.ResultsWe identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+tumors regardless of age, race, tumor size, and lymph node status.ConclusionsWe found that grade I PR+tumors are associated a<5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
引用
收藏
页码:671 / 677
页数:7
相关论文
共 33 条
  • [11] Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy
    Enewold, Lindsey
    Geiger, Ann M.
    Zujewski, JoAnne
    Harlan, Linda C.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2015, 151 (01) : 149 - 156
  • [12] A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay
    Gage, Michele M.
    Rosman, Martin
    Mylander, W. Charles
    Giblin, Erica
    Kim, Hyun-seok
    Cope, Leslie
    Umbricht, Christopher
    Wolff, Antonio C.
    Tafra, Lorraine
    [J]. CLINICAL BREAST CANCER, 2015, 15 (06) : 467 - 472
  • [13] Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer
    Kim, Hyun-seok
    Umbricht, Christopher B.
    Illei, Peter B.
    Cimino-Mathews, Ashley
    Cho, Soonweng
    Chowdhury, Nivedita
    Figueroa-Magalhaes, Maria Cristina
    Pesce, Catherine
    Jeter, Stacie C.
    Mylander, Charles
    Rosman, Martin
    Tafra, Lorraine
    Turner, Bradley M.
    Hicks, David G.
    Jensen, Tyler A.
    Miller, Dylan V.
    Armstrong, Deborah K.
    Connolly, Roisin M.
    Fetting, John H.
    Miller, Robert S.
    Park, Ben Ho
    Stearns, Vered
    Visvanathan, Kala
    Wolff, Antonio C.
    Cope, Leslie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4390 - +
  • [14] Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
    Klein, Molly E.
    Dabbs, David J.
    Shuai, Yongli
    Brufsky, Adam M.
    Jankowitz, Rachel
    Puhalla, Shannon L.
    Bhargava, Rohit
    [J]. MODERN PATHOLOGY, 2013, 26 (05) : 658 - 664
  • [15] Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
    Lamond, Nathan W. D.
    Skedgel, Chris
    Rayson, Daniel
    Lethbridge, Lynn
    Younis, Tallal
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1115 - 1123
  • [16] Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer - An economic analysis based on prognostic and predictive validation studies
    Lyman, Gary H.
    Cosler, Leon E.
    Kuderer, Nicole M.
    Hornberger, John
    [J]. CANCER, 2007, 109 (06) : 1011 - 1018
  • [17] 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy
    Mamounas, Eleftherios P.
    Liu, Qing
    Paik, Soonmyung
    Baehner, Frederick L.
    Tang, Gong
    Jeong, Jong-Hyeon
    Kim, S. Rim
    Butler, Steven M.
    Jamshidian, Farid
    Cherbavaz, Diana B.
    Sing, Amy P.
    Shak, Steven
    Julian, Thomas B.
    Lembersky, Barry C.
    Wickerham, D. Lawrence
    Costantino, Joseph P.
    Wolmark, Norman
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (04):
  • [18] Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
    Mamounas, Eleftherios P.
    Tang, Gong
    Fisher, Bernard
    Paik, Soonmyung
    Shak, Steven
    Costantino, Joseph P.
    Watson, Drew
    Geyer, Charles E., Jr.
    Wickerham, D. Lawrence
    Wolmark, Norman
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) : 1677 - 1683
  • [19] Routine Histopathologic Characteristics Can Predict Oncotype DX™ Recurrence Score in Subsets of Breast Cancer Patients
    Mattes, Malcolm D.
    Mann, Justin M.
    Ashamalla, Hani
    Tejwani, Ajay
    [J]. CANCER INVESTIGATION, 2013, 31 (09) : 604 - 606
  • [20] The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients
    Onoda, Toshinao
    Yamauchi, Hideko
    Yagata, Hiroshi
    Tsugawa, Koichiro
    Hayashi, Naoki
    Yoshida, Atsushi
    Suzuki, Koyu
    Sakurai, Osamu
    Nakamura, Seigo
    [J]. BREAST CANCER, 2015, 22 (04) : 406 - 412